Log In
Print
BCIQ
Print
Print this Print this
 

NAV4694 (formerly AZD4694)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFluorine-18 (F-18) labeled PET imaging agent that binds beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionDiagnostic; Imaging agent
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationNeurology, Diagnostic
Indication DetailsDetect beta amyloid plaque deposition in the brain to aid diagnosis of Alzheimer's disease (AD); Detect cerebral beta amyloid in end-of-life subjects with and without dementia; Predict progression to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI)
Regulatory Designation

Partner

Navidea Biopharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$22.5M

$5.0M

$17.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today